Few areas of cannabis research generate more parental interest — or more scientific caution — than autism spectrum disorder (ASD). Surveys of autism parent communities consistently show high rates of cannabis use for behavioral symptoms, driven largely by desperation with conventional pharmacology. The science is beginning to catch up.
The Israeli Research
Israel has produced the most rigorous ASD cannabis research to date, partly because it has a functioning medical cannabis program that allowed structured data collection. A 2019 study by Barchel et al. in Frontiers in Pharmacology followed 53 children with ASD using CBD-enriched cannabis oil (20:1 CBD:THC) over 66 days [1]. Self-injury and rage attacks improved in 67.6% of patients; hyperactivity improved in 68.4%; sleep problems improved in 71.4%; and anxiety improved in 47.1%.
A larger follow-up observational study of 188 ASD patients found that after 6 months of treatment, 30% reported significant improvement and 53.7% reported moderate improvement, with 8.6% reporting worsening [2]. These are observational findings — no control group — but the consistency across studies is notable.
Mechanism and Theoretical Basis
The endocannabinoid system plays a key role in social behavior, anxiety modulation, and repetitive behaviors in animal models. Several genetic studies have found endocannabinoid system dysregulation in ASD subpopulations, providing a plausible mechanistic basis for cannabinoid intervention.
Key Evidence Points
- Barchel 2019: CBD oil improved rage/self-injury in 67.6%, sleep in 71.4%, anxiety in 47.1% of ASD children [1]
- Aran 2019 follow-up (n=188): 83.7% reported significant or moderate improvement after 6 months [2]
- Studies are observational — no randomized placebo-controlled trials completed as of 2026
- Endocannabinoid system dysregulation documented in ASD genetic subpopulations
- Side effects reported: sleep disturbances (14%), irritability (9%), loss of appetite (9%)
What Remains Unknown
No double-blind, placebo-controlled RCT in ASD has been completed and published as of this writing. The existing evidence is promising but cannot support clinical recommendations. Pediatric cannabis use requires extreme caution — developing brains may be more vulnerable to cannabinoid effects, and long-term neurodevelopmental data does not exist.
Citations
- Aran A, Cayam-Rand D. Medical Cannabis in Children. Rambam Maimonides Med J. 2020;11(1):e0003. PubMed 32017660
- Barchel D, Stolar O, De-Haan T, et al. Oral Cannabidiol Use in Children With Autism Spectrum Disorder to Treat Related Symptoms and Co-morbidities. Frontiers in Pharmacology. 2019. doi:10.3389/fphar.2018.01521
- Aran A, Cassuto H, Lubotzky A, et al. Brief Report: Cannabidiol-Rich Cannabis in Children with Autism Spectrum Disorder and Severe Behavioral Problems. Journal of Autism and Developmental Disorders. 2018. doi:10.1007/s10803-018-3808-2
- Bar-Lev Schleider L, Mechoulam R, Saban N, et al. Real life Experience of Medical Cannabis Treatment in Autism: Analysis of Safety and Efficacy. Scientific Reports. 2019. doi:10.1038/s41598-018-37570-y
- Aran A, Harel M, Cassuto H, et al. Cannabinoid treatment for autism: a proof-of-concept randomized trial. Molecular Autism. 2021. doi:10.1186/s13229-021-00420-2